NASDAQ: KTTA
Pasithea Therapeutics Corp Stock Ownership - Who owns Pasithea Therapeutics?

Insider buying vs selling

Have Pasithea Therapeutics Corp insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Tiago MarquesChief Executive Officer2025-05-12960$0.83
$792.00Sell

1 of 1

KTTA insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when KTTA insiders and whales buy or sell their stock.

KTTA Shareholders

What type of owners hold Pasithea Therapeutics Corp stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Pd Joint Holdings LLC Series 2016a35.05%2,608,696$1.88MInsider
Eric Shahinian24.03%1,788,415$1.29MInsider
Lawrence Steinman17.23%1,282,174$923.17kInsider
Israel Maxx Abramowitz14.13%1,051,575$757.13kInsider
Avi Geller13.90%1,034,702$744.99kInsider
Dean Lazer12.13%902,600$649.87kInsider
Eric Lazer12.13%902,600$649.87kInsider
Yassine Bendiabdallah4.03%300,000$216.00kInsider
David Delaney3.06%227,521$163.82kInsider
Advisorshares Investments LLC2.60%193,547$139.35kInstitution

1 of 3

KTTA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
KTTA2.86%97.14%Net Selling
CMND10.96%0.00%
PALI0.93%90.65%
TCRT0.25%99.75%Net Buying
TTNP0.10%99.90%

Pasithea Therapeutics Stock Ownership FAQ

Who owns Pasithea Therapeutics?

Pasithea Therapeutics (NASDAQ: KTTA) is owned by 4.04% institutional shareholders, 136.92% Pasithea Therapeutics insiders, and 0.00% retail investors. Pd Joint Holdings LLC Series 2016a is the largest individual Pasithea Therapeutics shareholder, owning 2.61M shares representing 35.05% of the company. Pd Joint Holdings LLC Series 2016a's Pasithea Therapeutics shares are currently valued at $1.88M.

If you're new to stock investing, here's how to buy Pasithea Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.